The Office of the Indiana Attorney General announced Wednesday that the state will receive nearly $2.1 million in a multi-state settlement with GlaxoSmithKline LLC concerning three of its drugs.
The complaint and consent judgment filed alleges that GlaxoSmithKline violated state consumer protection laws by misrepresenting the uses and qualities of the asthma drug, Advair, and antidepressant drugs Paxil and Wellbutrin.
The settlement with the drugmaker nets 45 states – including Indiana – a total of $105 million.
“Pharmaceutical companies are required to only promote a prescription drug for uses that have been approved by the FDA,” Zoeller said. “Off-label marketing can put patients unnecessarily at risk, which is why those decisions are best left to the treating physician and not the pharmaceutical companies.”